Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 3/20 | 0.43 |
| ▸ | CCR5 | P51681 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2600343 | 0.91 | MAPT (0.46) | NPY5RCCR5MAPTALDH1A1 | |
| SCHEMBL2600358 | 0.91 | SMN1; SMN2 (0.39) | NPY5RCCR5MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL2600345 | 0.90 | CCR5 (0.39) | NPY5RCCR5MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL2600351 | 0.89 | RAB9A (0.39) | NPY5RCCR5RAB9AMAPTALDH1A1 | |
| SCHEMBL2600353 | 0.88 | ABL1 (0.40) | CCR5RAB9A | |
| SCHEMBL2600349 | 0.88 | ABL1 (0.40) | NPY5RCCR5RAB9A | |
| SCHEMBL2600346 | 0.87 | NPY5R (0.43) | NPY5RCCR5EPHX2ALDH1A1SMN1; SMN2 | |
| SCHEMBL2600327 | 0.87 | USP30 (0.47) | RAB9AMAPTALDH1A1SMN1; SMN2USP30 | |
| SCHEMBL2600337 | 0.87 | NPY5R (0.37) | NPY5RCCR5EPHX2MAPTALDH1A1 | |
| SCHEMBL2600330 | 0.86 | NPY5R (0.45) | NPY5RCCR5MAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372833-B2 | Urea derivative | SHIONOGI & CO., LTD. (JP) | 2013-02-12 | — | — | US | disclosed |
| US-8372833-B2 | Urea derivative | SHIONOGI & CO., LTD. (JP) | 2013-02-12 | — | — | US | disclosed |
| US-20120095231-A1 | UREA DERIVATIVE | YANO TOSHISADA (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120095231-A1 | UREA DERIVATIVE | YANO TOSHISADA (JP) | 2012-04-19 | — | — | US | disclosed |
| US-8088777-B2 | Urea derivative | SHIONOGI & CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-8088777-B2 | Urea derivative | SHIONOGI & CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20090203712-A1 | Urea Derivative | SHIONOGI &CO., LTD. | 2009-08-13 | — | — | US | disclosed |
| US-20090203712-A1 | Urea Derivative | SHIONOGI &CO., LTD. | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095231-A1 | UREA DERIVATIVE | NPY5R, NPY1R, NPY2R | NPY5R 1/4885CCR5 2116/4885EPHX2 4211/4885 |
| US-20090203712-A1 | Urea Derivative | NPY5R, NPY1R, NPY2R | NPY5R 1/4885CCR5 2081/4885EPHX2 4206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.